Kiniksa Pharmaceuticals, Ltd. beat EPS estimates 62% of the time across 16 reported quarters (10 beats, 6 misses), averaging +0.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.30 | $0.30 | +0.0% | Beat | Q2 FY26 call · transcript |
| Q1 FY26 | $0.18 | $0.27 | +50.0% | Beat | |
| Q4 FY25 | $0.29 | $0.17 | -41.4% | Miss | Q4 FY25 call · transcript |
| Q3 FY25 | $0.33 | $0.23 | -30.3% | Miss | |
| Q2 FY25 | $0.18 | $0.23 | +27.8% | Beat | |
| Q1 FY25 | not reported | $0.11 | not reported | not reported | |
| Q4 FY24 | $-0.06 | $-0.12 | -100.0% | Miss | |
| Q3 FY24 | not reported | $-0.18 | not reported | not reported | |
| Q2 FY24 | $-0.09 | $-0.06 | +33.3% | Beat | |
| Q1 FY24 | $-0.14 | $-0.25 | -78.6% | Miss | |
| Q4 FY23 | not reported | $0.04 | not reported | not reported | |
| Q3 FY23 | $-0.18 | $-0.20 | -11.1% | Miss |
Back to KNSA overview · KNSA holders · KNSA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.